Each of these drugs is forecast to rake in at least $9.5 billion in 2024. Investors looking to profit should pay attention to the pharmaceutical giants that sell them.
News & Analysis: Bristol-Myers Squibb
These stocks are leading the way in their respective areas in battling cancer.
There's more good news with the fight against cancer than you might think.
You'll be surprised by the answer.
Promising data suggest the company might be able to raise the bar in melanoma treatments.
And the analyst really likes one in particular.
They could be big winners for patient investors.
BMY earnings call for the period ending March 31, 2019.
The big drugmaker beat Wall Street estimates in the first quarter thanks to solid sales growth for its top blockbusters.
Drugmakers battle for patients.